News Releases

- 2019 - 

Oct 04 Verzenio™ (abemaciclib) significantly extends life by a median of 9.4 months for women with HR+, HER2- advanced breast cancer in MONARCH 2 study
Oct 02 EMGALITY™ (galcanezumab) now available in Canada for preventive treatment of migraine
Aug 14 Lilly announces superiority of TALTZ® (ixekizumab) versus TREMFYA® (guselkumab) in delivering total skin clearance at week 12 in topline results from head-to-head (IXORA-R) trial in people living with moderate to severe plaque psoriasis
Aug 08 VERZENIO™ (abemaciclib) available in Canada for metastatic breast cancer
Aug 08 Lilly announces positive results for Emgality™ (galcanezumab) from the CONQUER study in patients who failed previous migraine preventive treatments
Jun 14 Lilly presents positive results for Taltz® (ixekizumab) vs. Humira® (adalimumab) in a head-to-head (SPIRIT-H2H) superiority study in patients with active psoriatic arthritis at the European Congress of Rheumatology
   
Jun 10 Trulicity® (dulaglutide) significantly reduced major cardiovascular events for broad range of people with type 2 diabetes
   
May 22 Lilly’s mirikizumab met primary endpoint and key secondary endpoints in Phase 2 study, including reductions of gastrointestinal lesions
   
Feb 04 Lilly announces top-line Phase 3 results for baricitinib in patients with moderate to severe atopic dermatitis 


- 2018 -

Dec 17 Lilly announces positive top-line results for Taltz® (ixekizumab) vs. Humira® (adalimumab) in a head-to-head superiority study (SPIRIT-H2H) in patients with active psoriatic arthritis
   
Nov 06 New analysis estimates the positive impact of empagliflozin on prolonging life expectancy in adults with type 2 diabetes and established cardiovascular disease
   
Nov 05 Trulicity® (dulaglutide) demonstrates superiority in reduction of cardiovascular events for broad range of people with type 2 diabetes
   
Nov 01 With availability of Olumiant™ (baricitinib), Lilly brings new oral treatment option for Canadians living with rheumatoid arthritis
   
Oct 12 Eli Lilly Canada and Women in Biz Network partner to shift perceptions of rheumatoid arthritis in the workplace
   
Oct 09 Lilly’s investigational dual GIP and GLP-1 receptor agonist shows significant reduction in HbA1c and body weight in people with type 2 diabetes
   
Jun 20 Health Canada approves Taltz® (ixekizumab) for treatment of active psoriatic arthritis 
   
May 03 Convenient prefilled insulin pen with flexible half-unit dosing approved and available in Canada
   
Jan 24 LARTRUVOTM (olaratumab) approved in Canada for the treatment of advanced soft tissue sarcoma in adults


- 2017 -

Dec 12 New concentrated insulin approved and available for Canadian patients
   
Oct 26 What matters most to Canadians living with rheumatoid arthritis?
   
Oct 25 Deeper than just skin, World Psoriasis Day spotlights the disease’s human impact
   
Aug 31 Acclaimed musician and former American Idol in Toronto for a special performance for children with type 1 diabetes
   
Apr 18 New report reveals little progress on 2014 WHO psoriasis recommendations


- 2016 -

Aug 11 Health Canada approves new indication for JARDIANCE™ (empagliflozin) tablets for adults with type 2 diabetes and established cardiovascular disease
   
Jun 21 Health Canada’s approval of Taltz™ (ixekizumab) brings targeted therapy to Canadians living with moderate-to-severe plaque psoriasis
   
Jun 14 JARDIANCE® (empagliflozin) significantly reduced the risk of progressive kidney disease in adults with type 2 diabetes with established cardiovascular disease
   
Feb 16 Trulicity™, a once-weekly GLP-1 injectable medication, now available to help Canadians with type 2 diabetes manage their blood sugar


- 2015 -

Nov 30 Health Canada approves JARDIANCE™ (empagliflozin) tablets for adults with type 2 diabetes
   
Sep 21 New gastric cancer medicine approved and available for use in Canada
   
Apr 28 Canadian cancer patients and their families find hope in art